69,970 Shares in 10x Genomics $TXG Acquired by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio bought a new position in 10x Genomics (NASDAQ:TXG) in the second quarter, Holdings Channel.com reports. The fund bought 69,970 shares of the company’s stock, valued at approximately $2,683,000.

Several other hedge funds also recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of 10x Genomics by 806.4% in the first quarter. Royal Bank of Canada now owns 182,836 shares of the company’s stock valued at $1,597,000 after buying an additional 162,665 shares during the period. Goldman Sachs Group Inc. grew its holdings in 10x Genomics by 163.5% during the first quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company’s stock worth $5,634,000 after acquiring an additional 400,430 shares during the period. Focus Partners Wealth bought a new stake in 10x Genomics in the first quarter worth about $92,000. Legal & General Group Plc lifted its holdings in 10x Genomics by 5.7% in the 2nd quarter. Legal & General Group Plc now owns 110,864 shares of the company’s stock valued at $1,284,000 after acquiring an additional 5,985 shares during the last quarter. Finally, American Century Companies Inc. acquired a new stake in 10x Genomics in the 2nd quarter valued at about $933,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TXG has been the subject of several recent research reports. Stephens increased their target price on shares of 10x Genomics from $50.00 to $65.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Morgan Stanley increased their price objective on 10x Genomics from $37.00 to $40.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Royal Bank Of Canada started coverage on 10x Genomics in a report on Tuesday. They set a “sector perform” rating and a $70.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research report on Wednesday, June 24th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $40.57.

Insider Buying and Selling

In other 10x Genomics news, Director Shehnaaz Suliman sold 2,207 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $63.65, for a total value of $140,475.55. Following the completion of the sale, the director directly owned 29,515 shares of the company’s stock, valued at $1,878,629.75. The trade was a 6.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Serge Saxonov sold 10,486 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $63.69, for a total transaction of $667,853.34. Following the transaction, the chief executive officer owned 1,075,349 shares in the company, valued at approximately $68,488,977.81. This trade represents a 0.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 117,945 shares of company stock valued at $6,304,588. 8.84% of the stock is owned by company insiders.

10x Genomics Stock Down 0.9%

TXG stock opened at $62.65 on Friday. The company has a 50 day moving average of $50.92 and a two-hundred day moving average of $33.35. The company has a market cap of $8.16 billion, a price-to-earnings ratio of -106.18 and a beta of 2.08. 10x Genomics has a 12-month low of $11.16 and a 12-month high of $66.94.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.10. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%.The company had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. During the same period last year, the business earned $0.28 EPS. The business’s quarterly revenue was down 12.7% on a year-over-year basis. On average, research analysts anticipate that 10x Genomics will post -0.75 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.